Chaenomeles lagenaria

Other Names

Ayва японскаяBokeChaenomeles angustifoliaChaenomeles eugenioidesChaenomeles speciosaChaenomeles speciosa (Sweet) NakaiChinese quinceChinesische ZierquitteCognassier du JaponCoing du JaponCommon flowering quinceCotogno CineseCydonia japonica var. lagenariaCydonia japonica var. lagenaria (Loisel.) MakinoCydonia lagenariaCydonia lagenaria Loisel.Cydonia speciosaCydonia speciosa SweetCydonia umbatoDwergkweeFlowering quinceJapánbirsJapanese flowering quinceJapanese quinceJapaninruusukvitteniJapanische ZierquitteJapanse kweeKiinanruusukvitteniKvedeLille japankvaedeMarmeleiro do JapãoMu GuaMuguaPigwowiec japońskiPyrus japonicaPyrus speciosaTiē gěng hǎi tángTie geng mu guaZhou pi muguaZhoupi MuguaХеномелес японскийЯпонская айваカラボケボケ宣木瓜川木瓜木瓜木瓜 (boke)楙皱皮木瓜貼梗海棠贴梗木瓜贴梗海棠铁杆海棠铁脚梨铁脚海棠명자꽃명자나무산당화

Synopsis

Chaenomeles lagenaria (Flowering Quince / Mugua): A Comprehensive Reference

1. Identity, Taxonomy, and Botanical Description

1.1 Nomenclature and Synonymy

Chaenomeles lagenaria (Loiseleur) Koidzumi is often encountered under its widely used synonym Chaenomeles speciosa (Sweet) Nakai (1929); however, Chaenomeles lagenaria (1909) holds nomenclatural priority under ICN Article 11.3. The name was first formally published by G. Koidzumi in the Botanical Magazine (Shokubutsu-gaku zasshi), volume 23, page 173, in 1909. Its replaced basionym is Cydonia lagenaria Loisel., published in the Traité des Arbres et Arbustes (Duhamel), new edition, volume 6 (1815). Despite C. lagenaria's nomenclatural priority, Chaenomeles speciosa (Sweet) Nakai remains the name in predominant use across the scientific and pharmacological literature and in official pharmacopoeias, and the two names are treated as synonyms throughout this article.

Additional synonyms documented in botanical records include Cydonia japonica (Thunb.) Pers. var. lagenaria (Loisel.) Makino, Cydonia speciosa Sweet, and Pyrus japonica (non Thunb.). The genus Chaenomeles, a member of the Rosaceae family, consists of four accepted species: Chaenomeles speciosa (Sweet) Nakai, Chaenomeles thibetica Yü, Chaenomeles cathayensis Schneid., and Chaenomeles japonica (Thunb.) Lindl.

In pharmaceutical and herbal medicine contexts, the drug derived from the dried fruit of this species bears the Latin pharmaceutical name Chaenomelis Fructus (also written Fructus Chaenomelis) and is known in Chinese as Mugua (木瓜) or, more specifically, Zhoupi Mugua to distinguish it from related species. Common English names include flowering quince, Chinese quince, and Japanese quince.

1.2 Botanical Description and Natural Source

Chaenomeles speciosa, the flowering quince, Chinese quince or Japanese quince, is a thorny deciduous or semi-evergreen shrub native to eastern Asia. Native to East Asia, mainly several Chinese provinces, it is a thorny shrub to 3 m tall. The plants establish a very dense crown with a tangled jumble of branches that are either spiny or with spurs. The flowers come before the leaves and are usually red, but may be white or pink. The fruit is fragrant and looks similar to a small apple, although some cultivars have much larger, pear-shaped fruits.

Chaenomeles speciosa (Sweet) Nakai belongs to Rosaceae, mainly distributed in China and Myanmar, and it has been long used as food and medicine in China. Chaenomeles plants are adapted to diverse ecological zones, particularly the temperate areas of Korea, Japan, and China. In China, Chaenomeles speciosa is mainly planted in Chongqing, Anhui, and Hubei provinces. The species is also cultivated as an ornamental with numerous cultivars, and has been introduced to Europe, Japan, Korea, the USA, Mexico, and New Zealand.

The pharmaceutical raw material is the fruit. The fruit is collected in summer and autumn when it is greenish yellow, has a slightly fragrant smell and sour taste; the big fruit has wrinkled peels, purplish red color, a solid nature, and sour taste; it is sliced and used unprocessed.

1.3 Common Preparations and Dosage Forms

Mugua is a Chinese herbal medicine derived from the dried mature fruit of Chaenomeles speciosa (Sweet) Nakai. The dosage of Mu Gua is controlled at 6–9 g, and it can be made into decoctions, pills, medicinal liquors, or lotions. Beyond traditional drug forms, in the past few decades, cultivation of C. speciosa became a part of routine agriculture, fulfilling an ever-increasing demand from the industry, particularly for fruit juices, fruit tea, vinegar, and fruit preservation. Three traditional agricultural varieties are well known: Luohanji, Zimugua, and Changjun.

The fruit peel, flesh (endocarp), roots, seeds, bark, twigs, and flowers have all been used in various preparations. Peels of Chaenomeles contain more phenolics, flavonoids, and triterpenes, and show better antioxidant activity and α-glucosidase inhibitory activity than the fleshes.

2. Traditional and Historical Use

2.1 Origin in Chinese Classical Literature

Chaenomeles speciosa, a commonly used traditional Chinese medicine material, has the effects of stimulating the circulation of the blood and causing the muscles and joints to relax, as well as harmonizing the stomach and resolving dampness. It was first recorded in the Ming Yi Bie Lu (Miscellaneous Records of Famous Physicians) during the Northern and Southern Dynasties, and its cultivation history can be traced back to the Bencao Tujing in the Song Dynasty. It is a relatively practical Chinese herbal medicine, which first appeared in Mingyi Bie Lu around 420–589 AD.

2.2 Traditional Chinese Medicine (TCM) Applications

The dried fruits of Chaenomeles are one of the most important drugs in traditional Chinese medicine (TCM). They have been used for thousands of years to treat asthma, colds, sore throats, tuberculosis, mastitis, and hepatitis. In TCM, C. speciosa fruit is used to treat gastric disorders, dyspepsia, dysentery, enteritis, influenza, and rheumatic inflammation.

Dried Chaenomeles fruits have been used as traditional herbal medicines since centuries within mainland China to cure dysentery, prosopalgia, rheumatoid arthritis, cholera, beriberi, vitamin C deficiency syndrome, enteritis, and hepatitis.

In the classical TCM framework, the fruit is considered sour and warm in nature, entering the liver and spleen meridians. Its traditional actions are to dispel wind-damp, soothe tendons, activate collaterals, and resolve dampness for harmonizing the stomach. It specializes in removing dampness and is rated as an essential herb for treating dampness arthralgia characterized by spasm of tendons and vessels.

In TCM, flowering quince fruit (known as "mu gua") is believed to have properties that "dispel wind-dampness," "harmonize the stomach," and relieve symptoms such as soreness, pain, and stiffness, which are sometimes associated with the early stages of respiratory infections like the common cold. It is commonly included in herbal formulas aimed at alleviating cold and flu symptoms, often in combination with other botanicals.

Not only the leaves and fruits of C. speciosa, but various other parts including roots, seeds, bark twigs, and flowers all have a long history of use in treating many human ailments. The traditional indications thus span musculoskeletal, gastrointestinal, respiratory, and nutritional deficiency contexts. The traditional efficacy of Mugua, as analyzed through network pharmacology, mainly corresponds to four diseases: rheumatoid arthritis, diarrhea, edema, and emesis.

2.3 Adulteration and Quality Control in the TCM Tradition

The dried fruit of Chaenomeles speciosa, known as Chaenomelis Fructus or Zhoupi Mugua, is a type of TCM that is widely used to treat many diseases. Adulteration has historically been an issue in the supply chain of this herb. Oleanolic acid, ursolic acid, pomolic acid, corosolic acid, 3-O-acetylpomolic acid, and one unknown compound have been identified as critical markers for the discrimination of authentic Chaenomelis Fructus from its adulterant, Guangpi Mugua.

3. Key Constituents and Active Compounds

3.1 Overview of Phytochemical Diversity

A series of chemical constituents, including triterpenoids, phenolic and phenylpropionic acids, flavonoids, saccharides, essential oils, and alkaloids, have been isolated from this plant and some have already been evaluated for their biological activities. Various parts of Chaenomeles species have been reported to possess a diverse range of chemical constituents, numbering over 150 compounds so far.

3.2 Triterpenes

Triterpenes are the main constituents of the genus Chaenomeles, and 23 triterpenes have been identified, including oleanane and ursane types, which are frequent metabolites in all five Chaenomeles species. Both oleanolic and ursolic acids are regarded as markers for Chaenomeles species to identify, classify, and evaluate them.

Various triterpenes and phenolics are present in the plant extracts, especially ursolic and oleanolic acids, which are potential chemicals recognized even in the People's Republic of China Pharmacopoeia. According to the Chinese Pharmacopoeia 2020 (ChP 2020), the total content of oleanolic acid (OA, C₃₀H₄₈O₃) and ursolic acid (UA) serve as quality markers, with documented ranges of 1.5–33.9 mg/g and 4.7–27.3 mg/g respectively, depending on species analyzed. Additional triterpenes include betulinic acid, pomolic acid, corosolic acid, and 3-O-acetylpomolic acid.

3.3 Polyphenols and Flavonoids

Among 24 polyphenol compounds obtained from Chaenomeles fruits, 20 were flavan-3-ols (including catechin, epicatechin, and procyanidin oligomers). Total polyphenol content (TPC) reached 46.92 mg/g gallic acid equivalents (GAE) in C. speciosa, with epicatechin and procyanidin B2 as the main bioactive compounds. These two species exhibited strong free radical scavenging activities, and the antioxidant ability was significantly correlated to their total polyphenol contents.

Oleanolic acid, ursolic acid, protocatechuic acid, rutin, catechin, caffeic acid, syringic acid, epicatechin, hyperin, quercetin, kaempferol, and chlorogenic acid are main active compounds in Chaenomeles. Phytochemical investigation of fruits of Chaenomeles speciosa led to the isolation of 20 compounds including 5 flavonoids, 5 phenylpropanoids, 3 benzoic acid derivatives, 2 phloroglucinols, 2 purines, and 3 terpenoids.

3.4 Polysaccharides

C. speciosa is rich in polysaccharides, and it has been reported that polysaccharides in C. speciosa have antioxidant and anti-inflammatory activities. A water-soluble polysaccharide (CSP) successfully purified from Chaenomeles speciosa had a weight-average molecular weight of about 6.3 × 10⁴ Da and was composed of glucose (Glc), galactose (Gal), rhamnose (Rha), and arabinose (Ara) with a relative molar ratio of 4.6:1.3:0.8:0.5.

3.5 Other Phytochemicals

In the roots, the presence of daucosterol, ursolic acid, oleanolic acid, pomolic acid, prunasins, and epicatechins has been demonstrated. The leaves contain epicatechin and flavonol glycosides, while in the fruit, monoterpene glucosides, leucoanthocyanines, epicatechin, and roseoside are present. The fruits also contain organic acids (malic acid, tartaric acid, citric acid), pectins, vitamin C, and aromatic compounds. The main chemical compositions of Chaenomelis Fructus include flavonoids, triterpenes, phenylpropanoids, organic acids, and tannins.

4. Established and Proposed Mechanisms of Action

4.1 Anti-Inflammatory Pathways

IL-1β, IL-6, TNF, and epidermal growth factor receptor (EGFR) have been identified as shared inflammatory targets of the four main traditional indications of Mugua (rheumatoid arthritis, diarrhea, edema, and emesis). In preclinical cell studies, compounds including 3,4-dihydroxybenzoic acid, quercetin, and methyl 3-hydroxybutanedioic ester could inhibit the production of TNF-α by 22.73%, 33.14%, and 37.19% respectively at 5 μg/mL (P < 0.05), and quercetin showed an inhibitory rate of 39.79% on IL-6 release in RAW264.7 macrophage cells (P < 0.05).

G-protein-AC-cAMP regulated signaling has been suggested to have a major role in reducing inflammation and deterioration of joints in arthritis animal models. Intervention of intracellular signaling cascades in synoviocytes by glucosides of C. speciosa may consequently suppress the deterioration of bones and reduction of inflammation in autoimmune rat models.

A 2022 study investigated the effects and underlying mechanism of polysaccharides in Chaenomeles speciosa on pro-inflammatory cytokines and the MAPK pathway in complete Freund's adjuvant (CFA)-induced arthritis and LPS-induced NR8383 cells. This study represents a purely preclinical (animal and cell-based) investigation; no clinical translation has been confirmed.

4.2 Antioxidant Mechanisms

3,4-Dihydroxybenzoic acid displayed high inhibitory activity on DPPH free radicals with an IC₅₀ value of 1.02 μg/mL, and quercetin also showed significant inhibitory action on DPPH with an IC₅₀ value of 3.82 μg/mL. In correlation analyses, total phenolics, vanillic acid, catechin, ursolic acid, and oleanolic acid all contribute to DPPH radical scavenging capacity, gallic acid contributes to total ferric reducing antioxidant power, while total triterpenes, total saponins, chlorogenic acid, and ferulic acid contribute to α-glucosidase inhibitory activity.

4.3 Antiviral / Neuraminidase Inhibition

Triterpenoid compounds in C. speciosa can prevent viral infections through inhibiting sialidase in the virus neuraminidase protein. Quercetin showed significant inhibitory action on neuraminidase (NA), with an IC₅₀ value of 1.90 μg/mL, while 3,4-dihydroxybenzoic acid showed an IC₅₀ of 1.27 μg/mL against NA. These findings are from in vitro studies and have not been confirmed in clinical trials.

4.4 Antiparkinsonian Mechanism

Preclinical pharmacological work has identified a dopamine transporter inhibitory mechanism as relevant to the antiparkinsonian activity of C. speciosa extract. C. speciosa owns antiparkinsonian and transporter inhibitory properties, documented alongside antitumor, anti-inflammatory, antioxidant, hepatoprotective, antimicrobial, antinociceptive, and immunoregulatory properties. This work remains confined to preclinical models; no human clinical data on Parkinson's disease have been published.

4.5 Immunomodulatory Mechanisms

A water-soluble polysaccharide (CSP) from C. speciosa could inhibit the growth of S180 tumor transplanted in mice and increase the relative spleen index and body weight of tumor-bearing mice. ConA and LPS-induced splenocyte proliferation and peritoneal macrophage phagocytosis were enhanced after CSP administration. CSP treatment could improve delayed-type hypersensitivity (DTH) and promote the secretion of IL-2, TNF-α, and IFN-γ in serum. The overall findings suggest that the antitumor effect of CSP is associated with its potent immunostimulatory activity. These results are from an animal study (murine S180 sarcoma model).

5. Scientific Evidence by Area of Use

5.1 Inflammation and Rheumatic/Musculoskeletal Conditions

Evidence type: Predominantly animal (in vivo) and cell-based (in vitro). No large-scale, randomized human clinical trials identified.

Chaenomeles speciosa has long been used as an herbal medicine for treatment of rheumatoid arthritis, prosopalgia, and hepatitis. A study evaluated anti-inflammatory activities of different fractions of extract of C. speciosa using carrageenan-induced paw edema in rats. The 10% ethanol fraction (C3) was found to have stronger anti-inflammatory effects compared with other fractions at the same dose, with chlorogenic acid identified as one of the active constituents responsible for the anti-inflammatory effect using bioassay-guided fractionation by HPLC.

Compared with controls, fraction C3 demonstrated significant anti-inflammatory activity in the xylene-induced ear edema test (P < 0.01), acetic acid-induced peritoneal capillary permeability test, and the cotton pellet granuloma test in mice or rats (P < 0.01); it also showed marked analgesic activity in the acetic acid-induced abdominal contraction test and formalin-induced paw licking test (P < 0.05 or 0.01). However, fraction C3 showed no significant effect in the hot plate test in mice.

A 2022 study investigated polysaccharides in C. speciosa (CSP) on the MAPK pathway in CFA-induced arthritis. Acetic acid-induced writhing and CFA-induced paw edema were used to determine analgesic and anti-inflammatory activity, respectively. CFA rats were administered CSP (12.5, 25.0, and 50.0 mg/kg) daily for 3 weeks via oral gavage. The analgesic test was done using three different doses of the extract (50, 100, and 200 mg/kg). These are preclinical animal and cell-line studies; results cannot be directly extrapolated to human efficacy or safety.

Strength of evidence: Preliminary; all data are preclinical (animal models and cell culture). No published randomized controlled trials (RCTs) in humans were identified for this indication.

5.2 Antioxidant Activity

Evidence type: In vitro / chemical assay studies.

Total polyphenol content (TPC) reached 46.92 mg/g GAE in C. speciosa, with epicatechin and procyanidin B2 as main bioactive compounds. C. speciosa and C. thibetica exhibited equally strong free radical scavenging activities, and the antioxidant ability was significantly correlated to total polyphenol contents. These findings establish that the fruit is a chemically potent antioxidant in laboratory assays, but clinical translation to in vivo human antioxidant status has not been demonstrated in controlled trials.

Strength of evidence: Strong at the in vitro chemical level; no human clinical data available.

5.3 Blood Sugar Regulation (Antihyperglycemic / α-Glucosidase Inhibition)

Evidence type: In vitro enzyme inhibition studies.

Chaenomeles are enriched with antioxidants and α-glucosidase inhibitory activities, well documented in recent studies. Contents of total flavonoids, total phenolics, total triterpenes, total condensed tannin, and total saponins were determined by colorimetric method, while 5 phenolics, 2 triterpenes, and 3 flavonoids were identified and quantified by HPLC-MS and HPLC; total triterpenes, total saponins, chlorogenic acid, and ferulic acid were found to contribute to α-glucosidase inhibitory activity. These are in vitro enzyme-based experiments; clinical evidence in people with diabetes or pre-diabetes is absent from the published record.

Strength of evidence: Preliminary in vitro only; no clinical human data identified.

5.4 Antiviral and Anti-Influenza Activity

Evidence type: In vitro cell-based studies.

The dried fruit of Chaenomeles speciosa is a traditional herb, widely used for the treatment of rheumatoid arthritis, prosopalgia, and hepatitis. In laboratory studies, isolated compounds from the fruit showed neuraminidase inhibition — a validated antiviral target. 3,4-Dihydroxybenzoic acid displayed inhibitory activity on neuraminidase with IC₅₀ value of 1.27 μg/mL, and compounds including quercetin and methyl 3-hydroxybutanedioic ester could inhibit TNF-α production. Methyl-3-hydroxybutanedioic ester found in C. speciosa has been reported to possess strong anti-inflammatory effects particularly in inflammatory avian influenza and dyspepsia.

Strength of evidence: In vitro only; no clinical antiviral trials in humans identified.

5.5 Gastrointestinal Activity

Evidence type: In vitro / animal study data; one historical Chinese clinical observation mentioned but not accessible for full review.

Various organic acids (betulinic, oleanolic, and ursolic acids) are the active components in fruits of C. speciosa regarded as potent therapeutic candidates in treating LT-induced diarrhea. The reference databases mention a "clinical observation on the effect of Chaenomeles speciosa to 107 cases of acute bacillary" disease (cited as Guo C et al.), but this study was published in Chinese-language literature and its full methodology and results are not verifiable through available English-language sources.

Strength of evidence: Weak; animal/in vitro data for the antidiarrheal and gastrointestinal effects. Any human clinical data available are limited to Chinese-language case series not fully assessable in this review.

5.6 Antitumor and Immunomodulatory Activity

Evidence type: Animal (in vivo) and in vitro.

A water-soluble polysaccharide (CSP) purified from C. speciosa could inhibit the growth of S180 tumor transplanted in mice and increased relative spleen index and body weight of tumor-bearing mice. ConA and LPS-induced splenocyte proliferation and peritoneal macrophage phagocytosis were enhanced after CSP administration. CSP treatment could improve delayed-type hypersensitivity and promote the secretion of IL-2, TNF-α, and IFN-γ in serum. The antitumor effect was associated with potent immunostimulatory activity.

C. speciosa polysaccharides have significant health benefits in preclinical work, including antidiabetic, anti-inflammatory and analgesic, antitumor, and immunomodulatory effects. Polysaccharides exhibit the capacity of antitumor and immunomodulatory effects in laboratory studies.

Strength of evidence: Preclinical only (animal tumor model and cell culture). No clinical oncology trials have been published in humans.

5.7 Antiparkinsonian Activity

Evidence type: Preclinical animal/mechanistic study.

A published preclinical study (Zhao et al., 2008, Pharmacology, Biochemistry, and Behavior, 90:363–371) investigated dopamine transporter inhibitory and antiparkinsonian effects of common flowering quince extract. Pharmacological investigations demonstrated that C. speciosa possesses anti-inflammatory, antinociceptive, antimicrobial, antioxidant, immunoregulatory, antiparkinsonian, hepatoprotective, and antitumor properties. The antiparkinsonian findings relate to dopamine transporter modulation in preclinical systems and have not been evaluated in human clinical trials.

Strength of evidence: Preclinical only. No human clinical trials identified.

5.8 Hepatoprotective Activity

Evidence type: Preclinical.

Pharmacological investigations have demonstrated that plants in the genus Chaenomeles exhibit anti-inflammatory, analgesic, antioxidant, antihyperglycemic, antihyperlipidemic, gastrointestinal protective, antitumor, immunomodulatory, antibacterial, antiviral, hepatoprotective, neuroprotective, and other pharmacological activities. Hepatoprotective activity is documented in preclinical literature but has not been evaluated in controlled human studies.

Strength of evidence: Preclinical only.

6. Body Systems Associated

Musculoskeletal system: Traditional and pharmacological focus on rheumatic disease, joint inflammation, muscle cramps, and arthralgias; supported by animal in vivo evidence.
Gastrointestinal system: Traditional use for dysentery, enteritis, diarrhea, dyspepsia, vomiting, and stomach harmonization; organic acid content studied in vitro.
Immune system: Polysaccharide-mediated immunomodulation demonstrated in murine models; splenocyte proliferation, macrophage phagocytosis, and cytokine enhancement observed preclinically.
Respiratory system: Traditional use for asthma, colds, sore throats, and influenza; neuraminidase-inhibitory activity of isolated compounds shown in vitro.
Cardiovascular / metabolic system: α-Glucosidase inhibitory and antihyperlipidemic activities observed in vitro; oleanolic acid has documented anti-platelet aggregation effects in pharmacological literature.
Nervous system: Antiparkinsonian and dopamine transporter-modulatory effects demonstrated in preclinical (animal) work.
Liver: Hepatoprotective effects reported in preclinical models.

7. Dosage Forms and Reported Study Dosages

In traditional TCM use, the dosage of Mu Gua is controlled at 6–9 g of the dried fruit; it can be prepared as decoctions, pills, medicinal liquors, or lotions.

In preclinical pharmacological studies, the following dosages have been reported specifically in the source literature (animal models only; not translatable to human dosing):

CFA-induced arthritis rat studies used oral gavage of C. speciosa polysaccharide (CSP) at 12.5, 25.0, and 50.0 mg/kg daily for 3 weeks; analgesic testing used extract doses of 50, 100, and 200 mg/kg.
Anti-inflammatory fraction C3 (10% ethanol fraction) was evaluated in mouse/rat models using carrageenan-induced paw edema assays, with comparisons to control groups (no specific human-equivalent dose extrapolation published).

No controlled human clinical trials specifying dosage regimens were identified in accessible peer-reviewed sources. The 6–9 g per day figure is the officially stated TCM dose and is codified in traditional materia medica.

8. Safety Considerations and Interactions

8.1 General Safety Profile

The maximum accessible data concerning the chemical compositions and their broad pharmacological properties of C. speciosa plant parts is pretty restricted, making it more appealing for in-depth investigations. Formal toxicological profiling in humans is absent from the English-language peer-reviewed record. The plant and its fruit have a centuries-long history of use as both food and medicine in China without widely documented serious adverse events in the classical literature, but systematic safety studies (such as dose-escalation trials or formal adverse event monitoring) have not been published in internationally accessible sources.

8.2 Allergy

People who are allergic to Mu Gua should not take it. The fruit belongs to the Rosaceae family; individuals with known hypersensitivity to members of this family (including apples, pears, peaches, and related fruits) should be aware of potential cross-reactivity, though no peer-reviewed allergy studies were identified.

8.3 Drug Interactions (Reported)

Patients should avoid taking iron or lead-containing medicines concurrently with Mu Gua, based on traditional TCM compatibility rules. The mechanism proposed relates to the high organic acid (particularly malic acid and tartaric acid) content of the fruit, which may form insoluble complexes with metal ions, potentially altering bioavailability of these substances.

8.4 Pesticide Residue Concerns in the Pharmaceutical Supply

Production of minor crop varieties often requires intensive pesticide use, which raises serious concerns over food safety and human health. The postharvest drying process can evaporate water from products and lead to an increase in concentrations in final samples, and may even convert pesticides into more toxic metabolites. Maximum residue level (MRL) values are of limited use for postharvest monitoring, and assessment of pesticide residual behavior from cultivation to postharvest processing should be investigated. This is a documented quality-control concern for the dried pharmaceutical preparation of Chaenomelis Fructus.

8.5 Adulteration Risk

Adulteration has always been a challenge in the development of TCM. Research presents useful insights that may help solve the problem of adulteration during preparation of Chaenomelis Fructus. A systematic method has been developed for the quality control of Chaenomelis Fructus, representing a step toward solving adulteration problems to improve clinical safety and effectiveness.

8.6 Pregnancy, Lactation, and Special Populations

No peer-reviewed clinical data on the safety of Chaenomeles speciosa preparations in pregnancy, lactation, or pediatric populations were identified in the sources retrieved. The absence of evidence does not indicate safety in these groups; the data gap represents a significant limitation of the current evidence base.

9. Overall Assessment of Evidence Quality

The maximum accessible data concerning the chemical composition and the broad pharmacological properties of C. speciosa plant parts is pretty restricted, making it more appealing for in-depth investigations. The overwhelming body of evidence for Chaenomeles lagenaria / C. speciosa consists of:

In vitro chemical characterization: Well-established; compositional data are robust and reproducible.
In vitro bioactivity studies: Numerous, covering antioxidant, anti-inflammatory, antiviral, and enzyme-inhibitory properties; methodologically sound but not directly translatable to clinical outcomes.
Animal (in vivo) preclinical studies: Available for anti-inflammatory, analgesic, antitumor, antiparkinsonian, and immunomodulatory effects; provide mechanistic plausibility but require human translation.
Human clinical trials: Absent from the accessible peer-reviewed English-language literature for any specific indication. Some Chinese-language case series are referenced but not assessable for methodological quality in this review.

Species of the genus Chaenomeles have been known in China for thousands of years and their fruits are used in TCM. Interest in the fruits has increased in recent decades due to the possibility of cultivating several species in Europe, mainly in the Baltic countries. This increasing global interest highlights the need for rigorous clinical trials to validate traditional uses and determine safe and effective human dosing regimens.

References

Health Conditions

Health conditions that Chaenomeles lagenaria may help support.

No conditions available.

Body Systems

Body systems that Chaenomeles lagenaria may help support.

No body systems available.